- Home
- AVIR vs TSHA Comparison
AVIR vs TSHA Comparison
Compare AVIR & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- TSHA
- Stock Information
- Founded
- AVIR 2012
- TSHA 2019
- Country
- AVIR United States
- TSHA United States
- Employees
- AVIR N/A
- TSHA N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- AVIR Health Care
- TSHA Health Care
- Exchange
- AVIR Nasdaq
- TSHA Nasdaq
- Market Cap
- AVIR 284.6M
- TSHA 313.6M
- IPO Year
- AVIR 2020
- TSHA 2020
- Fundamental
- Price
- AVIR $3.24
- TSHA $1.53
- Analyst Decision
- AVIR Hold
- TSHA Strong Buy
- Analyst Count
- AVIR 1
- TSHA 8
- Target Price
- AVIR $6.88
- TSHA $6.63
- AVG Volume (30 Days)
- AVIR 505.9K
- TSHA 2.3M
- Earning Date
- AVIR 02-26-2025
- TSHA 11-13-2024
- Dividend Yield
- AVIR N/A
- TSHA N/A
- EPS Growth
- AVIR N/A
- TSHA N/A
- EPS
- AVIR N/A
- TSHA N/A
- Revenue
- AVIR N/A
- TSHA $9,915,000.00
- Revenue This Year
- AVIR N/A
- TSHA N/A
- Revenue Next Year
- AVIR N/A
- TSHA N/A
- P/E Ratio
- AVIR N/A
- TSHA N/A
- Revenue Growth
- AVIR N/A
- TSHA N/A
- 52 Week Low
- AVIR $2.75
- TSHA $1.19
- 52 Week High
- AVIR $4.60
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- AVIR 47.81
- TSHA 34.16
- Support Level
- AVIR $3.11
- TSHA $1.56
- Resistance Level
- AVIR $3.49
- TSHA $1.75
- Average True Range (ATR)
- AVIR 0.14
- TSHA 0.15
- MACD
- AVIR -0.00
- TSHA -0.02
- Stochastic Oscillator
- AVIR 26.58
- TSHA 10.00
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.